In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V
- 30 September 2010
- journal article
- research article
- Published by Elsevier BV in Experimental Hematology
- Vol. 38 (9), 744-755
- https://doi.org/10.1016/j.exphem.2010.05.006
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Mast cells and mastocytosisBlood, 2008
- Novel approaches in the treatment of systemic mastocytosisCancer, 2006
- Imatinib mesylate in the treatment of systemic mastocytosisCancer, 2006
- Inhibition of the ERK Pathway Promotes Apoptosis Induced by 2-Chloro-2′-Deoxyadenosine in the B-Cell Leukemia Cell Line EhebNucleosides, Nucleotides and Nucleic Acids, 2006
- PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effectsBlood, 2006
- Cutaneous adverse reaction to 2-chlorodeoxyadenosine with histological flame figures in patients with chronic lymphocytic leukaemiaJournal of the European Academy of Dermatology and Venereology, 2004
- Systemic MastocytosisAnnual Review of Medicine, 2004
- Cladribine therapy for systemic mastocytosisBlood, 2003
- Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasmNature Genetics, 1996
- Response to Interferon Alfa-2b in a Patient with Systemic MastocytosisNew England Journal of Medicine, 1992